StubHub has been upgraded to a 'Buy' rating following a roughly 60% year-to-date decline in its stock price. The company benefits from a dominant position in the ticket resale market, with over $10 billion in annual ticket sales driven by a shift toward experience-based spending. Expansion into primary ticketing and cost reduction efforts have improved profitability, pushing adjusted EBITDA margins into the mid-20% range. Trading at about $5 per share, StubHub presents a compelling valuation with increased gross merchandise sales guidance and a stronger balance sheet, making it attractive for investors seeking value amid market volatility.
StubHub's recent rating upgrade is presented here with Pluang's Consumer Cyclical sector market data as of Nov 14, 2026 00:51 WIB. Out of 134 priced US stocks in this sector on Pluang, 85 rose and 48 fell today. Notable movers include NIO at USD 2.92 with a 1-day change of -4.10% and a Pluang order activity of 17% Sell / 83% Buy, RENT at USD 2.34 down 3.70% with 25% Sell / 75% Buy, and PTON at USD 5.73 up 3.62%, with a typical hold time of 38 days.
Susan R. Burns, Ph.D., President of the University of Mount Saint Vincent, has been awarded the 2027 Courageous Leadership Award for her visionary and bold leadership. Since 2021, she has led the university through significant transformation, includi...
Solo, a company specializing in privacy-preserving human verification, has integrated its SDK into JellyJelly, a social video app co-founded by Venmo's co-founder. This integration ensures that every JellyJelly account belongs to a real, unique perso...
The U.S. market for AI-enabled ophthalmic diagnostic devices is projected to grow from $72.5 million in 2026 to $267.2 million by 2033, expanding at a 20.5% CAGR. Growth is driven by rising diabetes-related eye diseases, FDA clearances for autonomous...
The global medical display monitors market, valued at $2.8 billion in 2025, is projected to grow to $4.0 billion by 2033 with a CAGR of 4.6%. Growth is fueled by rising adoption of digital imaging systems, demand for accurate diagnostics, and healthc...
Oppenheimer downgraded Enovix from Outperform to Perform as the company expands production in South Korea and shifts focus to drone and smart-eyewear customers. Enovix reported a 38% revenue increase to $11 million in Q3 but saw its adjusted loss wid...
